EXTRAMEDULLARY MYELOMA:
CHALLENGES AND CAR-T
Extramedullary myeloma β plasma cell tumours outside the bone marrow β is more aggressive and harder to treat. CAR-T offers real but limited benefits; understanding the biology is essential.
analyticsAt a Glance
- check_circleExtramedullary myeloma poses specific challenges for CAR-T due to heterogeneous antigen expression
- check_circleBispecific CAR-T and combination approaches may improve outcomes in EMM
- check_circleEarly data from Chinese centres shows CAR-T responses in EMM, particularly for soft tissue plasmacytomas
- check_circleClose imaging follow-up alongside haematological monitoring is required after CAR-T in EMM
What Is Extramedullary Myeloma?
Extramedullary myeloma (EMD) refers to multiple myeloma that has spread beyond the bone marrow into soft tissues, organs, lymph nodes, or the bloodstream β present in ~10β30% of patients at some point.
Why EMD Is More Challenging
EMD cells have additional genetic changes enabling survival outside the bone marrow niche. More proliferative, more PI-resistant, and more likely to have low BCMA expression β directly affecting CAR-T efficacy.
Types of EMD
Paraosseous EMD: adjacent to bone, better prognosis. Extraosseous EMD: liver, kidney, skin, lymph nodes, CNS β more aggressive, shorter remissions, harder to treat.
CAR-T in EMD β What the Data Shows
Multiple Chinese trials have included EMD subgroups. Response rates are lower than marrow-confined disease but meaningful.
BCMA CAR-T in EMD
Response rates in EMD: ORR ~50β70% vs 80β90% in standard populations. Remission duration shorter. Low BCMA expression in EMD lesions is a contributing factor.
GPRC5D Advantage in EMD
GPRC5D expression is maintained in most EMD lesions even when BCMA is low. GPRC5D CAR-T and dual-target BCMA+GPRC5D show higher activity in EMD than BCMA-alone products.
Frequently Asked Questions
About Extramedullary Myeloma
Is CAR-T worth trying in extramedullary myeloma?
Yes, with realistic expectations. CAR-T β particularly GPRC5D-targeting or dual-target β is one of the best options for EMD. Response rates are lower and remissions shorter than in marrow-confined disease, but meaningful responses occur, especially with combination and consolidation strategies.
Should I test BCMA expression in my EMD lesions?
Yes. BCMA can be reduced or absent in EMD lesions compared to marrow. Confirming BCMA expression on specific EMD lesions before committing to BCMA-targeted therapy is valuable and increasingly available at specialist centres.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Dealing with Extramedullary Myeloma?
CancerFax reviews your myeloma history and EMD locations to identify appropriate GPRC5D or dual-target CAR-T trials in China.
For informational purposes only. Consult a haematologist before treatment decisions.